利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

31 条记录 (耗时 0.031 秒)

    IMIDAZOLE-2-THIONES
    6.
    发明申请
    IMIDAZOLE-2-THIONES 有权
    咪唑-2 -THIONES

    公开(公告)号：US20080091028A1

    公开(公告)日：2008-04-17

    申请号：US11873537

    申请日：2007-10-17

    申请人： Ken Chow ,  Todd Heidelbaugh ,  Daniel Gil ,  Michael Garst ,  Larry Wheeler

    发明人： Ken Chow ,  Todd Heidelbaugh ,  Daniel Gil ,  Michael Garst ,  Larry Wheeler

    IPC分类号： C07D215/12 ,  C07D215/02 ,  C07D215/22 ,  C07D233/06 ,  C07D233/30

    CPC分类号： C07D233/84 ,  C07D233/70 ,  C07D401/06 ,  C07D403/06 ,  C07D405/06 ,  C07D409/06 ,  C07D409/08

    摘要： Compounds of Formula 1 where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula 1 where X is O also have the advantageous property that they have no or only minimal cardivascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardivascular and/or sedatory activity.

    摘要翻译： 式1的化合物，其中X为S且变量具有本说明书中定义的含义，优先选择于α2B2和/或α2C2肾上腺素能受体 2A肾上腺素能受体，因此没有或仅有最小的血管内和/或镇静作用。 式1的这些化合物可用作哺乳动物（包括人）中的药物，用于治疗疾病和/或缓解对α2B2肾上腺素能受体的激动剂治疗有反应的病症。 其中X是O的式1化合物也具有它们没有或只有最小的血管内和/或镇静作用的有利性质，并且可用于治疗没有或仅有最小血管和/或镇静作用的疼痛和其它病症。

    IMIDAZOLE-2-THIONES
    7.
    发明申请
    IMIDAZOLE-2-THIONES 失效
    咪唑-2 -THIONES

    公开(公告)号：US20080097103A1

    公开(公告)日：2008-04-24

    申请号：US11873500

    申请日：2007-10-17

    申请人： Ken Chow ,  Todd Heidelbaugh ,  Daniel Gil ,  Michael Garst ,  Larry Wheeler

    发明人： Ken Chow ,  Todd Heidelbaugh ,  Daniel Gil ,  Michael Garst ,  Larry Wheeler

    IPC分类号： C07D233/84 ,  C07D401/02 ,  C07D405/06 ,  C07D409/02

    CPC分类号： C07D233/84 ,  C07D233/70 ,  C07D401/06 ,  C07D403/06 ,  C07D405/06 ,  C07D409/06 ,  C07D409/08

    摘要： Compounds of Formula 1 where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardiovascular and/or sedatory activity. These compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula 1 where X is O also have the advantageous property that they have no or only minimal cardiovascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardiovascular and/or sedatory activity.

    摘要翻译： 式1的化合物，其中X为S且变量具有本说明书中定义的含义，优先选择于α2B2和/或α2C2肾上腺素能受体 2A肾上腺素能受体，因此没有或仅有最小的心血管和/或镇静活性。 式1的这些化合物可用作哺乳动物（包括人）中的药物，用于治疗疾病和/或缓解对α2B2肾上腺素能受体的激动剂治疗有反应的病症。 其中X为O的式1的化合物也具有它们没有或只有最小的心血管和/或镇静活性的有利特性，并且可用于治疗没有或仅有最小的心血管和/或镇静活性的疼痛和其它状况。

    Agents and methods for enhancing photodynamic therapy
    10.
    发明申请
    Agents and methods for enhancing photodynamic therapy 审中-公开
    用于增强光动力疗法的药剂和方法

    公开(公告)号：US20060223750A1

    公开(公告)日：2006-10-05

    申请号：US11096886

    申请日：2005-04-01

    申请人： James Burke ,  Elizabeth Syage ,  Michael Garst ,  Larry Wheeler

    发明人： James Burke ,  Elizabeth Syage ,  Michael Garst ,  Larry Wheeler

    IPC分类号： A61K38/17 ,  A61K38/05 ,  A61K31/739 ,  A61K31/409 ,  A61K31/555 ,  C07K14/74 ,  C07K5/06

    CPC分类号： A61K41/0071 ,  A61K41/0057 ,  A61K47/543 ,  A61K47/61

    摘要： A chemical conjugate for administration to a patient undergoing photodynamic therapy includes a photoactive compound coupled to a leakage reducing agent that is structured to reduce leakage of the photoactive compound from a patient's vasculature. The leakage reducing agent may be a bulking agent to reduce, for example, sterically reduce, the permeability of the photoactive compound through the blood vessel, or it may be a ligand that binds to endothelial cells of a patient's choriocapillaries. The conjugate may be used in methods of reducing secondary damage associated with photodynamic therapy.

    摘要翻译： 用于给予经历光动力治疗的患者的化学共轭物包括偶联到减漏剂的光活性化合物，其被构造为减少光活性化合物从患者脉管系统的泄漏。 渗漏还原剂可以是填充剂，以减少（例如）空间地降低光活性化合物通过血管的渗透性，或者它可以是与患者绒毛膜毛细血管的内皮细胞结合的配体。 缀合物可用于减少与光动力疗法相关的次级损伤的方法。